Actinogen Medical Ltd
Research Actinogen Medical Ltd (ACW) on Bullrun: market cap AUD 168.27M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerACW
- ExchangeAU
- CountryAustralia
- SectorHealthcare
- IndustryBiotechnology
- CurrencyAUD
- Market capAUD 168.27M
- Financial periodFY2025
- Net income-AUD 14.73M
- Free cash flow-AUD 7.59M
Valuation Snapshot
latest market cap is AUD 168.27M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | n/a | -AUD 14.73M | -AUD 7.59M | n/a | 0 | AUD 16.50M | AUD 3.26M | AUD 18.34M |
| FY2024 | n/a | -AUD 13.04M | -AUD 16.96M | n/a | -0.01 | AUD 9.45M | AUD 319.07K | AUD 19.70M |
| FY2023 | n/a | -AUD 10.75M | -AUD 8.73M | n/a | -0.01 | AUD 8.46M | AUD 86.93K | AUD 13.41M |
| FY2022 | n/a | -AUD 9.50M | -AUD 9.52M | n/a | -0.01 | AUD 16.37M | AUD 165.27K | AUD 21.74M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-24 | AUD 168.27M | n/a | n/a | n/a |
About Actinogen Medical Ltd
Actinogen Medical Limited, a biotechnology company, develops therapies for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol in Australia. It develops Xanamem, an oral medication and inhibitor of the 11ß-HSD1 enzyme that achieves target engagement in the brain for the treatment of Alzheimer's disease, major depressive disorder, fragile x syndrome, and other neurological diseases.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Actinogen Medical Ltd's market cap?
Actinogen Medical Ltd's market capitalization is AUD 168.27M.
What does Actinogen Medical Ltd do?
Actinogen Medical Limited, a biotechnology company, develops therapies for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol in Australia. It develops Xanamem, an oral medication and inhibitor of the 11ß-HSD1 enzyme that achieves target engagement in the brain for the treatment of Alzheimer's disease, major depressive disorder, fragile x syndrome, and other neurological diseases. The company was formerly known as Actinogen Limited and changed its name to Actinogen Medical Limited in November 2015.